Sunday, June 1, 2025

Latest

Cognetivity Enters Paid Pilot Program With Japanese Insurance Giant

Cognetivity Neurosciences (CSE: CGN) appears to be on a roll when it comes to establishing pilot programs in new markets. Following the company entering a pilot program in Singapore earlier this month, the firm has now entered into a paid pilot program with a Japanese insurance giant.

The latest pilot program will be conducted with Mitsui Sumitomo Primary Life and Mitsui Sumitomo Aioi Life, which are both companies owned by MS&AD Insurance Group Holdings. MS&AD is viewed as a giant in the space, with over 13,000 employees and operations in fifty different countries and jurisdictions.

The program will see the firms OptiMind mobile app, which is based on the firms integrated cognitive assessment tech, deployed by MS&AD.

The purpose of the pilot program is to demonstrate the potential of the assessment tool for personal use, with the ultimate goal of deploying the tech at scale to the entire client base of MS&AD. Full deployment, of course, is contingent on the success of the pilot program.

The pilot program is being enacted through the venture arm of MS&AD, known as MS&AD Ventures, which provides support to the company and looks to discover advanced tech to add value to the model. The venture arm is set to confirm the utility of the app before deploying it through the Primary Life and Aioi Life subsidiaries.

“This is a very compelling deployment for us as it demonstrates that, through the use of our technology delivered on smartphones, users are able to measure their own brain function as part of their normal routine and adapt their lifestyle to maximize the performance of what is their most important organ and largest indicator of their overall health. Having more paid deployments in Asia adds to our growing commercial pipeline and provides strong additional validation of the global appeal of our technology,” commented CEO Sina Habibi.

Financial details of the pilot program were not provided, although the company did indicate it is a paid, pilot-based arrangement.

Cognetivity Neurosciences last traded at $0.335 on the CSE.


FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. We may buy or sell securities in the company at any time. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply

Video Articles

Alamos Gold Q1 Earnings: The Inside Scoop

Cerrado Gold Q4 Earnings: The Turnaround is Working

B2GOLD Q1 Earnings: Revenue Up, Production & Cash Flow Decline

Recommended

Canadian Copper: The $172M Combined Strategy PEA

ESGold Begins Concentration Tests Ahead Of First Production

Related News

Cognetivity Partners With UK National Health Service For New Remote Brain Health Clinic

Cognetivity Neuroscience (CSE: CGN) this morning indicated that it continues to see adoption of its...

Wednesday, July 14, 2021, 09:25:00 AM

Cognetivity’s Assessment Tool To Be Deployed At KetamineOne Clinics Across North America

Cognetivity Neurosciences (CSE: CGN) will soon see its cognitive assessment tool for the early detection...

Wednesday, September 1, 2021, 08:22:59 AM

Cognetivity Neurosciences Sees Granting Of FDA Clearance For Cognitive Assessment Tool

Cognetivity Neurosciences (CSE: CGN) has reached a major achievement. The company has been granted FDA...

Wednesday, October 20, 2021, 09:22:23 AM

Cognetivity: Utilizing AI for Early Alzheimer’s Intervention

Sina Habibi, Co-founder & CEO of Cognetivity Neurosciences (CSE: CGN) sits down with us today...

Wednesday, June 14, 2023, 01:30:00 PM

Cognetivity Sees Its Cognitive Tool Used In Clinical Study For OCD

While it may have been initially developed for the early detection of Alzheimer’s disease or...

Tuesday, September 13, 2022, 08:38:28 AM